Better Buy: Gilead or AbbVie

Gilead (GILD) and AbbVie (ABBV) are set to face off against one another with new therapies for hepatitis C, but is one a better buy than the other?

Mar 27, 2014 at 9:30AM

The hunt for a cure to hepatitis C has been one of the most active areas for drug development in recent years. Investments to develop a new class of oral treatments requiring shorter treatment periods and fewer side-effects spawned two newly approved drugs for the disease last year, including Gilead's (NASDAQ:GILD) highly anticipated Sovaldi.

The FDA could approve an additional therapy from AbbVie (NYSE:ABBV) this year too. The promise of these new hepatitis C treatments has helped drive shares to new highs, but with markets selling-off, investors may be getting the best opportunity to buy in a while, suggesting it may be a good time to consider whether one of the two companies is a better buy.

GILD Chart

GILD data by YCharts

Debating earnings
Both Gilead and AbbVie are highly successful drug developers with top selling therapies and deep product pipelines. Gilead generates $9 billion a year from it franchise of life-changing HIV drugs, and AbbVie's Humira is one of the world's top selling treatments, with annual sales north of $10 billion.

But it's Gilead that has the edge when it comes to transforming those sales into shareholder-friendly profit. Gilead's operating margin has been 40% over the past 12 months, roughly 10% higher than AbbVie's.

GILD Operating Margin (TTM) Chart

GILD Operating Margin (TTM) data by YCharts

Gilead's thick margin has analysts increasingly convinced that earnings will go sharply higher this year, especially given Sovaldi's encouraging inventory building in December. Despite only being on the market for one month last quarter, that inventory stock-piling resulted in Gilead recording $140 million in Sovaldi sales in Q4.

Based on the early results, analysts have increased their estimate for Gilead's 2014 earnings per share from $3.27 to $3.80 over the past 90 days. They've also boosted their outlook for 2015 too. Industry watchers are now expecting $5.69 in EPS for 2015, versus $5.18 predictions three months ago.

Their enthusiasm is a contrast to growing pessimism over AbbVie. AbbVie's top selling drug Humira is facing new competitors, including Johnson & Johnson's (NYSE:JNJ) Stelara. Johnson's Stelara won FDA approval for psoriasis in 2009 and for psoriatic arthritis in 2013, and sales of the drug marched 46% higher to $1.5 billion last year. Pfizer's Xeljanz, an oral treatment for rheumatoid arthritis approved in 2012 may also eat into Humira market share. And the FDA just recently approved Celgene's oral Otezla for psoriatic arthritis too.

Those competitive pressures, coupled with uncertainty as to whether AbbVie's three drug hepatitis C cocktail will come to market before Gilead's next two drug combination of Sovaldi and ledipasvir, has analysts ratcheting down their outlook for this year and next year. Over the past 90 days, analysts have taken expectation for AbbVie in 2014 down from $3.19 to $3.11. If AbbVie delivers on that estimate, it would mark a slight year-over-year decline from the $3.14 per share it earned in 2013.

Debating valuation
Despite expectations that AbbVie's earnings will flatten this year, analysts do think earnings will climb in 2015 to $3.62 per share. That means investors are only paying about 14 times next year earnings to buy AbbVie shares.

While that's far from pricey, Gilead appears even cheaper. Investors are only paying about 13 times forward earnings to own its shares.

Neither company is cheap relative to sales; however, Gilead holds an even bigger valuation advantage when considering the price to earnings relative to earnings growth, or PEG ratio. Typically, a PEG ratio south of 1 may indicate that investors are under-pricing the potential for earnings expansion. That means Gilead's 0.53 ratio is particularly attractive. AbbVie's is much higher, at 3.57.

Fool-worthy final thoughts
The race to deliver new combination therapies for hepatitis C designed to eliminate the use of side-affect laden interferon and ribavirin will heat up this year as both Gilead and AbbVie file for approval. Gilead sent along its application to the FDA in February, and AbbVie has been forecasting its submission will be filed by mid-year.

Since Gilead is likely to get the nod before AbbVie, investors are wise to wonder whether there will be enough room for AbbVie's cocktail to carve away significant sales in the indication, particularly given Bristol-Myers daclatisvir is also likely to be vying for market share. Given Gilead already has a substantial -- and growing -- slate of HIV drugs, an approval for Sovaldi, and may soon add a cancer fighting drug to its product lineup. Gilead appears to have a sales growth advantage, and its operating margin suggests a bottom line advantage too.

That suggests Gilead is the more attractive option of the two. However, a wild card exists in the form of payer pushback on Gilead's $84,000 price tag for Sovaldi. That said, price pressure isn't a new issue, for Gilead given its faced pricing scrutiny for its HIV drugs in the past.

3 stocks that could become your next huge winner
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have done it before with great biotech stocks. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

 

Todd Campbell owns Gilead. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.

The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers